Paola Rogliani to Drug Therapy, Combination
This is a "connection" page, showing publications Paola Rogliani has written about Drug Therapy, Combination.
Connection Strength
0.417
-
A potential role of triple therapy for asthma patients. Expert Rev Respir Med. 2019 11; 13(11):1079-1085.
Score: 0.074
-
Is ICS-LAMA an alternative option to treat patients with COPD? Lancet Respir Med. 2018 05; 6(5):316-317.
Score: 0.067
-
Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study. Pulm Pharmacol Ther. 2018 04; 49:20-26.
Score: 0.066
-
In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids. Evid Based Med. 2017 10; 22(5):183-184.
Score: 0.064
-
Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis. Respir Med. 2017 08; 129:189-198.
Score: 0.063
-
Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. Eur Respir J. 2018 12; 52(6).
Score: 0.018
-
Emerging antibacterial and antiviral drugs for treating respiratory tract infections. Expert Opin Emerg Drugs. 2018 09; 23(3):185-199.
Score: 0.017
-
Combining long-acting bronchodilators with different mechanisms of action: A pharmacological approach to optimize bronchodilation of equine airways. J Vet Pharmacol Ther. 2018 Aug; 41(4):546-554.
Score: 0.017
-
A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD. Expert Opin Drug Saf. 2018 05; 17(5):509-517.
Score: 0.017
-
Role of muscarinic antagonists in asthma therapy. Expert Rev Respir Med. 2017 03; 11(3):239-253.
Score: 0.015